Supplements that support serotonin production, emotional balance, and overall psychological wellbeing.
21 itemsA focused, evidence-based look at glycine’s potential to support deep (slow-wave) sleep and overall sleep architecture, with a brief comparison to CBT-I and other supplements.
Is burnout really “adrenal fatigue”? Evidence suggests burnout reflects HPA axis dysregulation and altered cortisol rhythms—not failing adrenal glands. Learn what studies show and where adaptogens like ashwagandha and rhodiola may fit, plus Ayurvedic/TCM perspectives.
A focused review of how meditation may reshape the brain’s stress hub—the amygdala—covering structural and functional neuroimaging, practice types, dose–response patterns, and clinical relevance.
Does oral GABA cross the blood–brain barrier? This focused review weighs human trials, BBB science, PharmaGABA vs synthetic, and GABA-supportive alternatives for natural calm.
Early human trials suggest Bifidobacterium longum 1714 may modulate stress responses and cognition via the gut–brain axis, with mechanistic links through the vagus nerve and inflammation. Traditional ferments like kimchi, kefir, and miso offer complementary, emerging evidence as proto-psychobiotics.
How sleep stages work, which supplements may influence onset, duration, or depth of sleep, and why CBT‑I remains the most evidence‑based strategy for chronic insomnia.
Neuroimaging and clinical trials suggest meditation may reshape attention and emotion circuits—supporting reductions in anxiety/depressive symptoms and echoing 2,500+ years of contemplative tradition.
Burnout through a physiological lens: how HPA axis dysregulation alters cortisol patterns, why “adrenal fatigue” isn’t a diagnosis, what trials show about ashwagandha and rhodiola, and how Eastern perspectives on qi/ojas align with stress biology.
Psychobiotics—specific Lactobacillus and Bifidobacterium strains—may modestly improve mood and stress via the gut–brain axis. Learn what the evidence says, how the vagus nerve and fermented foods fit in, and where traditional ferments like kimchi, kefir, and miso meet modern science.
GABA and Natural Calm: An evidence-based look at anxiety, whether oral GABA crosses the blood–brain barrier, pharmaGABA vs. synthetic, natural strategies like L-theanine and magnesium, benzodiazepines’ mechanism, and TCM/Ayurvedic herbs with GABAergic actions.
KSM-66 vs. Sensoril, golden root dosing, tulsi for cortisol — cutting through the hype on the most popular stress-balancing herbs.
Evidence-rated cognitive enhancers for focus, memory, and neuroprotection. What the clinical trials say and how to stack them safely.
Anxiety and stress exist on a continuum from adaptive, short-term arousal to persistent, impairing conditions such as generalized anxiety disorder (GAD) and panic disorder. Western biomedicine defines specific syndromes using standardized criteria and emphasizes evidence-based psychotherapy and pharmacotherapy. Eastern and traditional systems view anxiety as dysregulated mind–body energy or imbalance across organ systems, prioritizing practices that train attention, calm the autonomic nervous system, and restore resilience—often through meditation, breath, movement, and botanicals. A growing integrative model blends these strengths: pairing the robust symptom relief of cognitive behavioral therapy (CBT) and selective serotonin reuptake inhibitors (SSRIs)/serotonin–norepinephrine reuptake inhibitors (SNRIs) with mindfulness, yoga, and targeted herbal supports for stress physiology and sleep. In Western care, diagnosis relies on DSM-5-TR criteria. GAD features excessive, hard-to-control worry for at least six months with symptoms like restlessness, fatigue, muscle tension, irritability, poor concentration, and sleep disturbance. Panic disorder involves recurrent, unexpected panic attacks and persistent concern or behavioral change related to attacks. Clinicians exclude medical causes (e.g., hyperthyroidism, arrhythmias), substance effects, and assess functional impairment and comorbidity (depression, PTSD, substance use). First-line treatments with the strongest evidence are CBT (including exposure-based techniques) and SSRIs/SNRIs. CBT teaches skills to modify catastrophic thinking, increase tolerance of physical sensations, and reduce avoidance—producing large, durable effects across anxiety disorders. SSRIs/SNRIs reduce core symptoms but require weeks to full effect and can cause side effects (e.g., GI upset, sexual dysfunction). Benzodiazepines can relieve acute anxiety but carry dependence, cognitive, and accident risks, so guidelines reserve them for short-term
Depression (Major Depressive Disorder, MDD) is a common, potentially severe mood disorder marked by persistent low mood and/or loss of interest or pleasure, along with changes in sleep, appetite, energy, concentration, and thoughts of worthlessness or suicide. In Western medicine, MDD is diagnosed using DSM-5 criteria: at least five of nine symptoms present for two weeks or more, causing distress or impairment, with one being depressed mood or anhedonia, and not better explained by substances, a medical condition, or bipolar disorder. Severity ranges from mild to severe and may include specifiers (e.g., melancholic, peripartum, seasonal). Effective care is guided by symptom severity, patient preference, medical comorbidities, and past treatment response. Western approaches are highly evidence-based. Psychotherapies such as cognitive behavioral therapy (CBT), behavioral activation (BA), and interpersonal therapy (IPT) have strong support, particularly for mild to moderate depression; BA can be as effective as CBT and is often more scalable. First-line medications include selective serotonin reuptake inhibitors (SSRIs) like sertraline and escitalopram due to favorable tolerability; serotonin–norepinephrine reuptake inhibitors (SNRIs) are also common. Alternatives such as bupropion or mirtazapine can be chosen based on symptom profile (e.g., low energy or insomnia). In treatment-resistant depression (often defined after at least two adequate medication trials), evidence-based options include augmentation strategies (e.g., lithium or certain atypical antipsychotics), electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), and ketamine/esketamine. A stepped-care model is widely endorsed: start with low-intensity interventions for mild cases, step up to combined psychotherapy and pharmacotherapy as needed, and use somatic treatments for resistant or severe illness—always with ongoing symptom monitoring (e.g., PHQ-9) and safety checks. In “e
Attention-deficit/hyperactivity disorder (ADHD) and anxiety disorders frequently co-occur across the lifespan. In children and adolescents with ADHD, about one-quarter to one-third have a current a...
Chronic pain and depression frequently travel together, creating a bidirectional cycle where each condition can precipitate, amplify, and maintain the other. Epidemiologic studies show substantiall...
Depression and anxiety frequently travel together, share many risk factors, and respond to overlapping treatments. Epidemiologic studies show high bidirectional comorbidity: a large proportion of p...
Hypothyroidism and depression frequently overlap clinically and biologically. Thyroid hormones influence brain development, neurotransmission, and energy metabolism; when thyroid levels are low (ov...
IBS and anxiety frequently travel together through a shared gut–brain axis. IBS is a disorder of gut–brain interaction defined by recurrent abdominal pain with altered bowel habits, while anxiety e...
Migraines and depression frequently co-occur and influence one another in clinically meaningful ways. Population studies consistently show a bidirectional association: people with migraine have abo...
Parkinson’s disease (PD) and depression frequently co-occur and influence each other’s course, symptoms, and treatment choices. Depression is among the most common non-motor symptoms of PD, affecti...
